Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,010 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Keizman D, et al. Among authors: berger r. Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10. Eur J Cancer. 2012. PMID: 22409947
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen R, Berger R. Keizman D, et al. Among authors: berger r. Cancer Res Treat. 2016 Jan;48(1):281-7. doi: 10.4143/crt.2014.289. Epub 2015 Mar 5. Cancer Res Treat. 2016. PMID: 25761478 Free PMC article.
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT, Chi KN, Joshua AM. Leibowitz-Amit R, et al. Among authors: berger r. J Transl Med. 2016 Jan 13;14:12. doi: 10.1186/s12967-015-0747-y. J Transl Med. 2016. PMID: 26762579 Free PMC article. Clinical Trial.
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B. Paluch-Shimon S, et al. Among authors: berger r. Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25. Breast Cancer Res Treat. 2016. PMID: 27113739
Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
Leibowitz-Amit R, Israel A, Gal M, Atenafu EA, Symon Z, Portnoy O, Laufer M, Dotan Z, Ramon J, Avni D, Fridman E, Berger R. Leibowitz-Amit R, et al. Among authors: berger r. Clin Oncol (R Coll Radiol). 2016 Dec;28(12):790-796. doi: 10.1016/j.clon.2016.07.007. Epub 2016 Aug 5. Clin Oncol (R Coll Radiol). 2016. PMID: 27498850
4,010 results